Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey
Table 2
Results regarding definition and diagnosis of AD.
Item
Consensus (%)
Discrepancy (%)
(i) AD can also develop de novo in adults or young adults, or even in advanced age
93.6
(ii) AD is a multifaceted disease that is derived from the interactions of multiple factors, including the skin components (cellular and extracellular components that form the skin barrier)
96.8
(iii) AD is a multifaceted disease that is derived from the interactions of multiple factors, including the immune system (innate and adaptative)
97.6
(iv) AD is a multifaceted disease that is derived from the interactions of multiple factors, including the skin microbiome
89.6
(v) AD is a multifaceted disease that is derived from the interactions of multiple factors, including genetic factors
98.4
(vi) AD is a multifaceted disease that is derived from the interactions of multiple factors, including environmental factors
98.4
(vii) Currently, the diagnosis and assessment of the severity of AD are made on clinical grounds
97.6
(viii) The clinical criteria defined by Hanifin and Rajka are used for the clinical diagnosis of AD
94.3
(ix) The clinical presentation of AD depends on the age of the patients
92.8
(x) With greater frequency, children < 2 years of age and adults present involvement of the face and neck; in addition, adults also present involvement of the flexor and extensor surfaces
94.3
(xi) Some forms of presentation seen in adults include dermatitis of the head and neck, chronic eczema of the hands, and multiple zones of lichenification or prurigo
96.8
(xii) The classification of “intrinsic” AD (not associated with IgE) and “extrinsic” AD (associated with IgE) has practical implications related to specific avoidance strategies in the management of the disease
60.0
(xiii) The blood eosinophil count is not a useful biomarker in AD
(xiv) Currently there are no validated biomarkers that help in the diagnosis of AD
83.2
AD: atopic dermatitis; IgE: immunoglobulin E. 37.1% of disagreement.
